217 related articles for article (PubMed ID: 31174878)
21. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?
Schumacher MC; Burkhard FC; Thalmann GN; Fleischmann A; Studer UE
Eur Urol; 2006 Aug; 50(2):272-9. PubMed ID: 16632187
[TBL] [Abstract][Full Text] [Related]
22. Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions.
Suardi N; Larcher A; Haese A; Ficarra V; Govorov A; Buffi NM; Walz J; Rocco B; Borghesi M; Steuber T; Pini G; Briganti A; Mottrie AM; Guazzoni G; Montorsi F; Pushkar D; Van Der Poel H;
Eur Urol; 2014 Oct; 66(4):635-43. PubMed ID: 24411992
[TBL] [Abstract][Full Text] [Related]
23. Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Clin Cancer Res; 2018 May; 24(10):2342-2349. PubMed ID: 29463560
[No Abstract] [Full Text] [Related]
24. [Outcome after radical prostatectomy with extended pelvic lymphadenectomy for untreated high-risk clinically localized prostate cancer].
Tsurusaki T; Yamasaki Y; Maruta S
Nihon Hinyokika Gakkai Zasshi; 2013 May; 104(3):496-504. PubMed ID: 23819361
[TBL] [Abstract][Full Text] [Related]
25. Who Should Get Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiation?
Malakorn S; Yang Y; Bednarski BK; Kaur H; You YN; Holliday EB; Dasari A; Skibber JM; Rodriguez-Bigas MA; Chang GJ
Dis Colon Rectum; 2019 Oct; 62(10):1158-1166. PubMed ID: 31490825
[TBL] [Abstract][Full Text] [Related]
26. [Complications of pelvic lymphadenectomy in clinically localised prostate cancer: different techniques in comparison and dependency on the number of removed lymph nodes].
Winter A; Vogt C; Weckermann D; Wawroschek F
Aktuelle Urol; 2011 May; 42(3):179-83. PubMed ID: 21409742
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of pelvic lymph node status in prostate cancer: review of 1690 cases.
Maccio L; Barresi V; Domati F; Martorana E; Cesinaro AM; Migaldi M; Iachetta F; Ieni A; Bonetti LR
Intern Emerg Med; 2016 Apr; 11(3):399-404. PubMed ID: 26875178
[TBL] [Abstract][Full Text] [Related]
28. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial.
Lestingi JFP; Guglielmetti GB; Trinh QD; Coelho RF; Pontes J; Bastos DA; Cordeiro MD; Sarkis AS; Faraj SF; Mitre AI; Srougi M; Nahas WC
Eur Urol; 2021 May; 79(5):595-604. PubMed ID: 33293077
[TBL] [Abstract][Full Text] [Related]
29. Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer.
Chenam A; Ruel N; Pal S; Barlog J; Lau C; Wilson T; Yuh B
Can J Urol; 2018 Jun; 25(3):9340-9348. PubMed ID: 29900823
[TBL] [Abstract][Full Text] [Related]
30. Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.
Izol V; Ok F; Aslan G; Akdogan B; Sozen S; Ozden E; Celik O; Muezzinoglu T; Turkeri L; Akdogan N; Baltaci S
Prostate; 2022 May; 82(7):763-771. PubMed ID: 35188993
[TBL] [Abstract][Full Text] [Related]
31. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
[TBL] [Abstract][Full Text] [Related]
32. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.
Briganti A; Karakiewicz PI; Chun FK; Suardi N; Gallina A; Abdollah F; Freschi M; Doglioni C; Rigatti P; Montorsi F
Int J Urol; 2009 Aug; 16(8):676-81. PubMed ID: 19602006
[TBL] [Abstract][Full Text] [Related]
33. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
Preisser F; van den Bergh RCN; Gandaglia G; Ost P; Surcel CI; Sooriakumaran P; Montorsi F; Graefen M; van der Poel H; de la Taille A; Briganti A; Salomon L; Ploussard G; Tilki D;
J Urol; 2020 Feb; 203(2):338-343. PubMed ID: 31437119
[TBL] [Abstract][Full Text] [Related]
34. The learning curve for laparoscopic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer: implications for compliance with existing guidelines.
Eden CG; Zacharakis E; Bott S
BJU Int; 2013 Aug; 112(3):346-54. PubMed ID: 23419154
[TBL] [Abstract][Full Text] [Related]
35. The factors that affect the prediction of lymph node metastasis in prostate cancer.
Turk H; Ün S; Koca O; Cinkaya A; Kodaz H; Zorlu F
J Cancer Res Ther; 2018; 14(5):1094-1098. PubMed ID: 30197355
[TBL] [Abstract][Full Text] [Related]
36. Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer.
Washington SL; Cowan JE; Herlemann A; Zuniga KB; Masic S; Nguyen HG; Carroll PR
Prostate; 2021 Feb; 81(2):102-108. PubMed ID: 33075151
[TBL] [Abstract][Full Text] [Related]
37. Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection.
Porcaro AB; Tafuri A; Panunzio A; Mazzucato G; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Serafin E; Cianflone F; Orlando R; Gentile I; Migliorini F; Zecchini Antoniolli S; Di Filippo G; Brunelli M; Pagliarulo V; Cerruto MA; Antonelli A
Int Urol Nephrol; 2022 Mar; 54(3):541-550. PubMed ID: 35044553
[TBL] [Abstract][Full Text] [Related]
38. Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis.
Wettstein MS; David LA; Pazhepurackel C; Qureshi AA; Zisman A; Nesbitt M; Saba K; Herrera-Caceres JO; Fankhauser CD; Ahmad A; Hamilton RJ; Eberli D; Zlotta AR; Sulser T; Fleshner NE; Poyet C; Finelli A; Hermanns T; Kulkarni GS
Prostate; 2021 Apr; 81(5):286-294. PubMed ID: 33599318
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of robot-assisted laparoscopic extended pelvic lymph node dissection for prostate Cancer.
Sigg S; Lehner F; Keller EX; Saba K; Moch H; Sulser T; Eberli D; Mortezavi A
BMC Urol; 2024 Jan; 24(1):24. PubMed ID: 38287319
[TBL] [Abstract][Full Text] [Related]
40. Free-indocyanine green-guided pelvic lymph node dissection during radical prostatectomy.
Claps F; de Pablos-Rodríguez P; Gómez-Ferrer Á; Mascarós JM; Marenco J; Collado Serra A; Casanova Ramón-Borja J; Calatrava Fons A; Trombetta C; Rubio-Briones J; Ramírez-Backhaus M
Urol Oncol; 2022 Nov; 40(11):489.e19-489.e26. PubMed ID: 36175317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
